Industry
Biotechnology
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
June 10, 2024 | 12:04 pm
Portfolio Pulse from Benzinga Newsdesk
May 17, 2024 | 2:17 pm
Portfolio Pulse from Benzinga Newsdesk
May 16, 2024 | 12:10 pm
Portfolio Pulse from Avi Kapoor
May 10, 2024 | 4:44 pm
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 7:16 pm
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 9:53 am
Portfolio Pulse from Benzinga Newsdesk
May 07, 2024 | 12:09 pm
Portfolio Pulse from Benzinga Newsdesk
April 23, 2024 | 10:26 am
Portfolio Pulse from Benzinga Newsdesk
April 11, 2024 | 11:27 am
Portfolio Pulse from Benzinga Newsdesk
April 10, 2024 | 11:06 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.